Exhibit (a)(1)(M)

Omnicare, Inc. · 100 East RiverCenter Boulevard · Covington, Kentucky 41011 · 859/392-3300 · 859/392-3360 Fax

Omnicare news release

OMNICARE INTENDS TO RE-FILE HART-SCOTT-RODINO NOTIFICATION

Omnicare Extends Tender Offer for NeighborCare Until July 30, 2004

COVINGTON, Ky., June 25, 2004 – Omnicare, Inc. (NYSE: OCR) today announced that it has withdrawn and intends to re-file its Hart-Scott-Rodino notification with respect to Omnicare’s tender offer for all of the outstanding shares of NeighborCare, Inc. (NASDAQ: NCRX) common stock for $30.00 per share in cash. Omnicare intends to re-file the notification with the Federal Trade Commission (“FTC”) on Monday, June 28, 2004. The re-filing will start a new 15-day waiting period that would be expected to expire at 11:59 p.m. on Tuesday, July 13, 2004, unless the FTC shortens or extends the waiting period.

The Hart-Scott-Rodino statute typically affords the U.S. antitrust enforcement agencies 30 calendar days to review an acquisition. However, when the first step of the transaction is a cash tender offer, as is the case here, that review period is shortened to 15 calendar days. Withdrawing and then re-filing the notification will give the FTC a full 30-day review period.

Omnicare also today announced that it has extended its offer for all of the outstanding shares of NeighborCare common stock. The offer, which was scheduled to expire at 5:00 p.m., New York City time, on Wednesday July 7, 2004, has been extended until 5:00 p.m., New York City time, on Friday, July 30, 2004, unless further extended.

As previously announced, Omnicare commenced a tender offer on June 4, 2004 for all of the outstanding shares of NeighborCare common stock for $30 per share in cash. This price represents a 70% premium over NeighborCare’s closing stock price on May 21, the last day of trading before the offer was made public on May 24. It is also a 40% premium over the 30-day trading average prior to the announcement of the offer, a 30% premium to Wall Street’s median price target for NeighborCare’s stock over the next 12 months and $4.00 more than NeighborCare’s previous all-time high.

As of the close of business on June 25, 2004, a total of 720 shares of NeighborCare common stock had been tendered.

Dewey Ballantine LLP is acting as legal counsel to Omnicare and Lehman Brothers and Lazard are acting as financial advisors. Innisfree M&A Incorporated is acting as information agent for Omnicare’s offer.

About Omnicare, Inc.

Omnicare, Inc. (NYSE:OCR), a Fortune 500 company based in Covington, Kentucky, is a leading provider of pharmaceutical care for the elderly. Omnicare serves residents in long-term care facilities comprising approximately 1,050,000 beds in 47 states and the District of Columbia, making it the nation’s largest provider of professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other institutional healthcare providers. Omnicare also provides clinical research services for the pharmaceutical and biotechnology industries in 29 countries worldwide.

This press release contains certain statements which are “forward-looking” statements under the federal securities laws and involve risks and uncertainties relating to the occurrence of future events. These statements include, but are not limited to, the impact of the NeighborCare acquisition on Omnicare’s earnings in 2004 and beyond; Omnicare’s ability to build upon its existing operations; geographic expansion opportunities; Omnicare’s ability to leverage services and capabilities among its national network of institutional pharmacies; Omnicare’s ability to successfully integrate this acquisition and achieve synergies; and Omnicare’s strategy in the institutional pharmacy business. Certain factors that could cause actual events not to occur as expressed in the forward-looking statements include, but are not limited to, the inability to integrate the NeighborCare acquisition as anticipated; the inability to realize expected revenues, earnings, synergies and other benefits from the NeighborCare acquisition; the performance of Omnicare’s institutional pharmacy business; business conditions in the institutional pharmacy industry generally; the inability to expand geographically as anticipated; the inability to leverage services and capabilities among Omnicare’s network of institutional pharmacies as anticipated; the effectiveness of Omnicare’s strategy in the institutional pharmacy business; and the ability of the NeighborCare acquisition to strengthen relationships with pharmaceutical and biotechnology companies. Omnicare assumes no obligation to update the forward-looking information. Other risks and uncertainties concerning Omnicare’s performance are set forth in reports and documents filed by Omnicare with the Securities and Exchange Commission from time to time. Please use caution in placing reliance on forward-looking statements.

This document is neither an offer to purchase nor a solicitation of an offer to sell securities. The tender offer is being made only through an offer to purchase and related letter of transmittal. Investors and security holders are strongly advised to read the tender offer materials of Omnicare because they contain important information. The tender offer materials have been filed by Omnicare with the Securities and Exchange Commission (SEC). Investors and security holders may obtain a free copy of these materials and other relevant documents on the SEC’s web site at: http://www.sec.gov. The tender offer materials and related documents may also be obtained for free by directing such requests to Omnicare at (859) 392-3331.

Contacts:

Cheryl Hodges Omnicare (859) 392-3331 Joele Frank / Steve Silva Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

#  #  #